Next 10 |
home / stock / cmiiu / cmiiu news
SomaLogic to debut on Nasdaq as a leading publicly traded AI-data driven proteomics platform company Business combination results in approximately $630 million in gross cash proceeds to catalyze organic and inorganic growth initiatives Combined company to trade on ...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
NEW YORK and BOULDER, Colo., Aug. 23, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc. (“SomaLogic” or the “Company”), a leader in AI-data driven proteomics technology, today announced that with the approach of the business combina...
BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its...
NEW YORK & BOULDER, Colo., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that the registration statement for their business combination has been declared effective by the US Se...
SPAC CM Life Sciences III (NASDAQ:CMLT), which is backed by Corvex's Keith Meister and Casdin Capital, agreed to a deal to take drug-price startup EQRx public. The transaction is expected to provide up to $1.8B in cash proceeds for EQRX, according to a statement. The deal includes a $1....
NEW YORK and BOULDER, Colo., Aug. 02, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, a leader in AI-data driven proteomics technology, today announced the appointment of Shaun Blakeman as the company’s Chief Financial Officer. “We are thrille...
Proteomics has the potential to revolutionize medicine in potentially the same way that genomics has. The traditional field looks primed for disruption and that effort could hit critical mass soon. Quantum-Si has set forth a business plan to utilize consumables as the primary driver o...
CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking the power of the company’s prot...
A team with a track record of prior success has raised its largest SPAC yet. The SPAC is about two months old, meaning it is becoming more likely to do a deal going forward. Because of the track record and the reputation of the team, the warrants are trading relatively rich. ...
News, Short Squeeze, Breakout and More Instantly...
CM Life Sciences II Inc. Unit Company Name:
CMIIU Stock Symbol:
NASDAQ Market:
CM Life Sciences II Inc. Unit Website:
SomaLogic to debut on Nasdaq as a leading publicly traded AI-data driven proteomics platform company Business combination results in approximately $630 million in gross cash proceeds to catalyze organic and inorganic growth initiatives Combined company to trade on ...
NEW YORK and BOULDER, Colo., Aug. 23, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc. (“SomaLogic” or the “Company”), a leader in AI-data driven proteomics technology, today announced that with the approach of the business combina...
BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its...